Here are the 424B prospectus supplements from Coya Therapeutics, Inc. (COYA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow COYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COYA filings page.
Coya Therapeutics, Inc. has filed a prospectus supplement to offer up to $30,000,000 of common stock through a sales agreement with Leerink Partners under its existing $75,000,000 shelf registration. The shares may be sold from time to time as an at-the-market offering at prevailing market prices.
The prospectus supplement cites 23,457,183 shares outstanding as of May 1, 2026, notes a last reported sale price of $4.11 per share on May 8, 2026, and illustrates an example sale of 7,299,270 shares raising $30.0 million (before commissions). Leerink Partners will act as sales agent (or principal) and receive a 3.0% commission on gross proceeds. Net proceeds are intended for working capital and clinical development.
Coya Therapeutics files a resale prospectus to register 2,522,727 shares of common stock for resale by selling stockholders. The registration covers 2,522,727 shares issued in a private placement on January 30, 2026 and states the Company will not receive any proceeds from resales.
The prospectus notes 23,457,183 shares outstanding as of March 10, 2026 and discloses a Nasdaq last sale price of $4.27 on March 19, 2026. The registration permits the selling stockholders to sell shares in various manners described under the Plan of Distribution.